In vitro studies confirm that linagliptin suppresses the proliferation of several tumor cell lines, including colorectal cancer HCT116, breast cancer MCF-7, and liver cancer HepG2, via mechanisms that involve cell cycle arrest and apoptosis induction [96]
6 Clinical evidence: from epidemiological promise to trial disappointment The progression of semaglutide from a metabolic medication to a prospective neurotherapeutic agent has been marked by a notable and challenging discrepancy between observational data and randomized controlled trial (RCTs) outcomes
The traditional classification of DM is mainly based on abnormalities in insulin secretion and action, such as type 1 DM due to an absolute lack of insulin secretion and T2DM due to insulin resistance and relative insulin deficiency
If an ingredient is on the label, it earned its place
We began exploring the efficacy of senolytics in tauopathy mouse models to determine the impact of senescent cells on brain structure and function relevant to AD neuropathology (35)
albicans and reverse its drug resistance [165]
)
